| 1 |
Liu J, Mu W, Gao T, Fang Y, Zhang N, Liu Y. CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma. Pharmaceutics 2023;15. [PMID: 36839748 DOI: 10.3390/pharmaceutics15020426] [Reference Citation Analysis]
|
| 2 |
Ling J, Jiang Y, Yan S, Dang H, Yue H, Liu K, Kuang L, Liu X, Tang H. A novel pH- and glutathione-responsive drug delivery system based on in situ growth of MOF199 on mesoporous organic silica nanoparticles targeting the hepatocellular carcinoma niche. Cancer Nano 2022;13. [DOI: 10.1186/s12645-022-00139-6] [Reference Citation Analysis]
|
| 3 |
Chang S, Hu H, Chen Y, Yen Y, Huang N. Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02504-6] [Reference Citation Analysis]
|
| 4 |
Shah SHBU, Alavi M, Hajarizadeh B, Matthews GV, Martinello M, Danta M, Amin J, Law MG, George J, Valerio H, Dore GJ. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100552] [Reference Citation Analysis]
|
| 5 |
Wong SN, Chua-Tan ML, Hadloc MA. Unchanging prevalence of late presentation to care among patients with chronic hepatitis B. Indian J Gastroenterol 2022;41:362-8. [PMID: 36129613 DOI: 10.1007/s12664-021-01231-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen M, Zhuang G, Seto W, Zhang L. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Global Health 2022;10:e278-87. [DOI: 10.1016/s2214-109x(21)00517-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 7 |
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. Int J Mol Sci 2021;22:9472. [PMID: 34502379 DOI: 10.3390/ijms22179472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 8 |
Chen P, Fang Q, Chen D, Chen H. Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. WJGO 2021;13:498-508. [DOI: 10.4251/wjgo.v13.i7.498] [Reference Citation Analysis]
|
| 9 |
Chen P, Fang QX, Chen DB, Chen HS. Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(7): 673-683 [PMID: 34322196 DOI: 10.4251/wjgo.v13.i7.673] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 10 |
Lapointe-Shaw L, Chung H, Holder L, Kwong JC, Sander B, Austin PC, Janssen HLA, Feld JJ. Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time. Hepatology 2021;73:2141-54. [PMID: 32931613 DOI: 10.1002/hep.31557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Lapointe-Shaw L, Chung H, Sander B, Kwong JC, Holder L, Cerocchi O, Austin PC, Feld JJ. Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. Liver Int 2021;41:33-47. [PMID: 32956567 DOI: 10.1111/liv.14670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Hamadeh A, Haines A, Feng Z, Thein HH, Janjua NZ, Krahn M, Wong WWL. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat 2020;27:1419-29. [PMID: 32810886 DOI: 10.1111/jvh.13373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 13 |
Li N, Wu JJ, Chen TT, Li XQ, Du JJ, Shan S, Wei W, Sun WY. GRK2 Suppresses Hepatocellular Carcinoma Metastasis and Invasion Through Down-Regulation of Prostaglandin E Receptor 2. Onco Targets Ther 2020;13:9559-71. [PMID: 33061439 DOI: 10.2147/OTT.S266641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 14 |
Innes H, Morling J, Aspinall E, Goldberg D, Hutchinson S, Guha I. Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival. Public Health 2020;187:165-71. [DOI: 10.1016/j.puhe.2020.07.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 15 |
Cai Y, Xia J, Wang N, Zhou H. Identification of prognostic alternative splicing signatures in hepatitis B or/and C viruses related hepatocellular carcinoma. Genomics 2020;112:3396-406. [PMID: 32525024 DOI: 10.1016/j.ygeno.2020.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol 2020;72:1088-96. [PMID: 31981727 DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 17 |
Zhang C, Ren Q, Chang W. Epidemiological Features and Risk Factors for Acquiring Hepatitis B, Hepatitis C, and Syphilis in HIV-Infected Patients in Shaanxi Province, Northwest China. Int J Environ Res Public Health 2020;17:E1990. [PMID: 32197326 DOI: 10.3390/ijerph17061990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 18 |
Song SS, Ying JF, Zhang YN, Pan HY, He XL, Hu ZM, Wang HJ, Dou XB, Mou XZ. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:3181-8. [PMID: 32256814 DOI: 10.3892/ol.2020.11430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 19 |
Wilton J, Samji H, Yu A, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort team. Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis". J Hepatol 2019;71:1256-8. [PMID: 31653445 DOI: 10.1016/j.jhep.2019.09.015] [Reference Citation Analysis]
|
| 20 |
Lapointe-Shaw L, Austin PC, Chung H, Sander B, Kwong JC, Feld JJ. Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis. J Hepatol 2019;71:1251-4. [PMID: 31648817 DOI: 10.1016/j.jhep.2019.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Hamadeh A, Feng Z, Krahn M, Wong WWL. A model-based framework for chronic hepatitis C prevalence estimation. PLoS One 2019;14:e0225366. [PMID: 31751393 DOI: 10.1371/journal.pone.0225366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Zhong Y, Li Y, Song T, Zhang D. MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. Physiol Genomics 2019;51:500-5. [PMID: 31251699 DOI: 10.1152/physiolgenomics.00019.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. Aliment Pharmacol Ther 2019;49:1126-33. [PMID: 30843268 DOI: 10.1111/apt.15201] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY. Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer 2019;19:286. [PMID: 30922251 DOI: 10.1186/s12885-019-5508-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 25 |
Krajden M, Cook D, Janjua NZ. Contextualizing Canada’s hepatitis C virus epidemic. CanLivJ 2018;1:218-30. [DOI: 10.3138/canlivj.2018-0011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 26 |
Chen G, Cai Z, Li Z, Dong X, Xu H, Lin J, Chen L, Zhang H, Liu X, Liu J. Clonal evolution in long-term follow-up patients with hepatocellular carcinoma. Int J Cancer. 2018;143:2862-2870. [PMID: 30183077 DOI: 10.1002/ijc.31844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 27 |
Schanzer D, Pogany L, Aho J, Tomas K, Gale-Rowe M, Kwong JC, Janjua NZ, Feld J. Impact of availability of direct-acting antivirals for hepatitis C on Canadian hospitalization rates, 2012-2016. Can Commun Dis Rep 2018;44:150-6. [PMID: 31011295 DOI: 10.14745/ccdr.v44i78a01] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 28 |
Binka M, Butt ZA, Wong S, Chong M, Buxton JA, Chapinal N, Yu A, Alvarez M, Darvishian M, Wong J, McGowan G, Torban M, Gilbert M, Tyndall M, Krajden M, Janjua NZ. Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada. World J Gastroenterol 2018; 24(11): 1216-1227 [PMID: 29568202 DOI: 10.3748/wjg.v24.i11.1216] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 29 |
Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio HM, Hajarizadeh B, Hayes PC, Krajden M, Amin J, Law MG, George J, Goldberg DJ, Hutchinson SJ, Dore GJ. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. J Hepatol 2018;68:393-401. [PMID: 29107152 DOI: 10.1016/j.jhep.2017.10.019] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
|
